Iron metabolism: pathophysiology and pharmacology

Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene

(2020) Ashutosh Lal et al.   BLOOD

Proton Pump Inhibition for Secondary Hemochromatosis in Hereditary Anemia, a Phase III Placebo Controlled Randomized Cross-over Trial in Progress

(2020) Annelies J. Van Vuren et al.   BLOOD

Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia

(2020) João Arezes et al.   BLOOD

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

(2020) M. Domenica Cappellini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?

(2020) Marvin Edeas et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer

(2020) Ginette S. Santiago-Sánchez et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives

(2019) Luigi Naldini   EMBO Molecular Medicine

Iron in Neurodegeneration – Cause or Consequence?

(2019) Alain Ndayisaba et al.   Frontiers in Neuroscience

First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis

(2019) Lutz Renders et al.   PLoS One

FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels

(2019) Vicenta Trujillo-Alonso et al.   Nature Nanotechnology

Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis

(2019) Priya Handa et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction

(2019) Francesca Vinchi et al.   EUROPEAN HEART JOURNAL

Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease

(2019) Matthew Sheetz et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dietary iron restriction leads to a reduction in hepatic fibrosis in a rat model of non-alcoholic steatohepatitis

(2019) Naomichi Abe et al.   Biology Open

Hepcidin and its therapeutic potential in neurodegenerative disorders

(2019) Zhong‐Ming Qian et al.   MEDICINAL RESEARCH REVIEWS

New insights into the role of iron in inflammation and atherosclerosis

(2019) Anne Cornelissen et al.   EBioMedicine

Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers

(2019) Frank Richard et al.   AMERICAN JOURNAL OF HEMATOLOGY

Renal clearable nanochelators for iron overload therapy

(2019) Homan Kang et al.   Nature Communications

CRISPR’s “magnificent moment” in the clinic

(2019) Mark Zipkin   NATURE BIOTECHNOLOGY

A Potential Therapy for Beta-Thalassemia (ST-400) and Sickle Cell Disease (BIVV003)

(2018) Michael C. Holmes et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Alpha-synuclein inhibits Snx3–retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson’s disease

(2018) Dhaval Patel et al.   HUMAN MOLECULAR GENETICS

Iron and Cancer

(2018) Suzy V. Torti et al.   Annual Review of Nutrition

Anemia of inflammation

(2018) Guenter Weiss et al.   BLOOD

Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase 2, open-label, dose-finding study

(2018) Maria Domenica Cappellini et al.   HAEMATOLOGICA

Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload

(2018) Andrew J. Schwartz et al.   JOURNAL OF CLINICAL INVESTIGATION

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer

(2018) Xinbing Sui et al.   Frontiers in Pharmacology

Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment

(2017) Lucia De Franceschi et al.   European Journal of Internal Medicine

Iron and infection

(2017) Tomas Ganz   INTERNATIONAL JOURNAL OF HEMATOLOGY

Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer’s disease mice

(2017) Yongli Xie et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

(2017) Saroj Vadhan-Raj et al.   Journal of Hematology & Oncology

Chronic Kidney Disease

(2017) Angela C Webster et al.   LANCET

SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways

(2017) Kai You et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Targeting iron metabolism in drug discovery and delivery

(2017) Bart J. Crielaard et al.   NATURE REVIEWS DRUG DISCOVERY

Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals

(2017) Anthony S. Grillo et al.   SCIENCE

Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages

(2017) Milene Costa da Silva et al.   Frontiers in Immunology

Ferroptosis: process and function

(2016) Y Xie et al.   CELL DEATH AND DIFFERENTIATION

Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis

(2016) Xiang Xue et al.   Cell Metabolism

Transferrin receptor 1: a target for antibody-mediated cancer therapy

(2016) Tracy R Daniels-Wells et al.   Immunotherapy

Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues

(2016) Saeid Zanganeh et al.   Nature Nanotechnology

Inflammatory processes in cardiovascular disease: a route to targeted therapies

(2016) Neil Ruparelia et al.   Nature Reviews Cardiology

Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism

(2016) Zuzana Rychtarcikova et al.   Oncotarget

Current and future alternative therapies for beta-thalassemia major

(2016) Edouard de Dreuzy et al.   Biomedical Journal

An important role of the hepcidin–ferroportin signaling in affecting tumor growth and metastasis

(2015) Wenli Guo et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease

(2015) F. Vinchi et al.   BLOOD

Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women

(2015) D. Moretti et al.   BLOOD

Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells

(2015) David L. Schonberg et al.   CANCER CELL

Anemia: progress in molecular mechanisms and therapies

(2015) Vijay G Sankaran et al.   NATURE MEDICINE

Iron-Deficiency Anemia

(2015) Clara Camaschella   NEW ENGLAND JOURNAL OF MEDICINE

Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia

(2015) Antoine N. Saliba et al.   Expert Review of Hematology

Decreased expression of ferroportin in prostate cancer

(2015) DONG XUE et al.   Oncology Letters

Targeting cancer by binding iron: Dissecting cellular signaling pathways

(2015) Goldie Y.L. Lui et al.   Oncotarget

MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis

(2015) Iryna Kindrat et al.   Oncotarget

Safe mobilization of CD34+ cells in adults with  -thalassemia and validation of effective globin gene transfer for clinical investigation

(2014) F. Boulad et al.   BLOOD

Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel

(2014) E. Angelucci et al.   HAEMATOLOGICA

The role of iron in brain ageing and neurodegenerative disorders

(2014) Roberta J Ward et al.   LANCET NEUROLOGY

Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia

(2014) Hitesh Soni   MEDICAL HYPOTHESES

Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis

(2014) Scott J Dixon et al.   eLife

The role of iron and reactive oxygen species in cell death

(2013) Scott J Dixon et al.   Nature Chemical Biology

Systemic Iron Homeostasis

(2013) Tomas Ganz   PHYSIOLOGICAL REVIEWS

Iron and Reactive Oxygen Species: Friends or Foes of Cancer Cells?

(2012) Laura M. Bystrom et al.   ANTIOXIDANTS & REDOX SIGNALING

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

Hypoxia-Inducible Factor-2α Mediates the Adaptive Increase of Intestinal Ferroportin During Iron Deficiency in Mice

(2011) Matthew Taylor et al.   GASTROENTEROLOGY

Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis

(2011) M. Mastrogiannaki et al.   HAEMATOLOGICA

Correction: Alpha-Synuclein Is a Cellular Ferrireductase

(2011) Paul Davies et al.   PLoS One

Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway

(2010) L. A. Cohen et al.   BLOOD

Divalent metal transporter 1 is a hypoxia-inducible gene

(2010) Zhong-Ming Qian et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Binding and uptake of H-ferritin are mediated by human transferrin receptor-1

(2010) Li Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

(2010) Z. K. Pinnix et al.   Science Translational Medicine

Intestinal Hypoxia-Inducible Transcription Factors Are Essential for Iron Absorption following Iron Deficiency

(2009) Yatrik M. Shah et al.   Cell Metabolism

Interaction of the Hereditary Hemochromatosis Protein HFE with Transferrin Receptor 2 Is Required for Transferrin-Induced Hepcidin Expression

(2009) Junwei Gao et al.   Cell Metabolism

Scara5 Is a Ferritin Receptor Mediating Non-Transferrin Iron Delivery

(2009) Jau Yi Li et al.   DEVELOPMENTAL CELL

Lipocalin 2 promotes breast cancer progression

(2009) J. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA